Company: IMRX
Filing Date: 2025-08-13
Form Type: S-3
Source: 0001104659-25-077655
Chunk: 49

Company: Immuneering Corp
Filing Date: 2025-08-13
Form: S-3
Chunk 49
---
 clinical trials on the timelines we expect;

•

our limited experience in designing and conducting clinical trials;

•

the timing of the initiation, progress and potential results of our ongoing and planned preclinical studies and clinical trials and our research programs, including our Phase 1/2a clinical trials of atebimetinib (IMM-1-104);

•

our ability to successfully complete our clinical trials, including our Phase 1/2a clinical trials of atebimetinib (IMM-1-104);

•

the risk of substantial delays in completing, if at all, the development and commercialization of our current or future product candidates;

•

risks related to adverse events, toxicities or other undesirable side effects caused by our current or future product candidates;

•

the risk of delays or difficulties in the enrollment and/or maintenance of patients in clinical trials;

<div align='center'>S-8</div>

TABLE OF CONTENTS

•

our substantial reliance on the successful development of our current and future product candidates, as well as our platform, including our proprietary technologies;

•

risks related to competition in our industry;

•

the market opportunity for our product candidates, if approved;

•

risks related to manufacturing;

•

risks related to our reliance on third parties;

•

risks related to our intellectual property;

•

risks related to ongoing and future pandemics or other widespread adverse health events; and

•

other important risk factors that could affect the outcome of the events set forth in these statements and that could affect our operating results and financial condition are described under the heading “Risk Factors” contained in this prospectus supplement and in the documents incorporated by reference herein.

We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. We cannot guarantee future results, levels of activity, performance or achievements, and you should not place undue reliance on our forward-looking statements. Our actual results may differ significantly from the results discussed in the forward-looking statements.

Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as may be required by law, we have no plans to update our forward-looking statements to reflect events or circumstances after the date of this prospectus supplement. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made.

<div align='center'>S